Pathological waste products

The term "Pathological waste products" refers to a broad and heterogeneous category of substances that accumulate in tissues and fluids as a result of disease, aging, or metabolic failure, rather than a single specific molecular target [1][2]. In the context of neurobiology, it frequently describes toxic protein aggregates like amyloid-beta and tau in Alzheimer’s disease, which are often cleared via the glymphatic or meningeal lymphatic systems [2][3][7]. Beyond neurology, the term encompasses uremic toxins in chronic kidney disease and undegraded metabolites within lysosomes in storage disorders [1][4]. Because it denotes a diverse collection of proteins, lipids, and small molecules, it lacks a singular structure or binding site for drug development [4][6]. Therapeutic approaches are instead directed at specific constituents within this category, such as using monoclonal antibodies for amyloid removal or enhancing natural clearance pathways like autophagy and lymphatic drainage [3][5]. Consequently, it is classified as an incorrect therapeutic target entry due to its lack of molecular specificity.

Other names

Cellular wasteToxic metabolitesMetabolic wasteProtein aggregatesUremic toxinsBiohazardous wasteCellular debris

Drugs targeting components of pathological waste typically act through monoclonal antibody-mediated clearance of specific proteins, osmotic diuresis, or physical removal via extracorporeal systems such as dialysis.